Cosmecca Korea Expects 12% Rise in Q3 Operating Profit; Target Price ₩140,000–Sangsangin
Predicted impact: Medium
Forecast 12% rise in Q3 operating profit; a modest, expected change.
241710 · KOSDAQ · ₩241710 · 코스메카코리아
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−34.3% from the high
₩62,900Today: ₩101,800 – ₩107,700₩155,500
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
Estimated leveraged-ETF rebalance on Oct 26: sell ₩688M at the close (5.3% of 20-day average trading value)
On its 24 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 5.9% of trading value and pointed the same way 14 of 24 times.
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Held by 11 funds.
Estimated from the funds' index or underlying stock.
Cosmecca Korea (코스메카코리아, KRX: 241710) is listed on KOSDAQ, in the Cosmetics sector. Cosmecca Korea is a Korean cosmetics ODM/OEM manufacturer that produces products for a range of domestic and global beauty brands, and it offers what it calls a global total service that accounts for each sales country's trends, distribution, and legal rules. Its shares closed at ₩102,200 on Oct 26, 2026, down 2.01% on the day, giving it a market value of ₩1.1T.
Cosmecca Korea is a Korean cosmetics ODM/OEM manufacturer that produces products for a range of domestic and global beauty brands, and it offers what it calls a global total service that accounts for each sales country's trends, distribution, and legal rules. The company uses its own automated production system and holds many international quality and management certifications, and it has production sites in Korea, China, and the United States, the latter through its 2018 acquisition of Inglewood Lab in New Jersey.
Written by AI from the company's latest annual report.
Predicted impact: Medium
Forecast 12% rise in Q3 operating profit; a modest, expected change.
Predicted impact: Low· Actual: −1.3% vs sector, volume 0.6× normal (5 trading days)
Joint R&D on emulsifier; no revenue size or commercial terms disclosed.
Predicted impact: Low· Actual: +0.6% vs sector, volume 0.8× normal (5 trading days)
Broker target raise on resolving supply disruption; small, vague, no size given.
Titles in Korean until English translations are added.
Also known as: Cosmecca Korea / 코스메카코리아 / 241710 / KRX:241710
Source: KRX statistical information